Phase III data show efficacy/safety of iclaprim in patients with complicated …
Arpida announced results from two pivotal phase III clinical trials that showed intravenous iclaprim, a novel antibiotic, had high clinical cure rates similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A new drug application for iclaprim in cSSSI will be discussed at the US FDA Anti-Infective Drugs Advisory Committee meeting on Nov. 20, 2008.
More: continued here
Monday, October 27th, 2008